Key facts
- Septest’s last known valuation is $3.7M (Mar 2026).
- It has raised $550K; the latest was Early Stage VC ($550K) in Mar 2026.
- Notable investors include Kappika Ventures, Oxford Technology Management, University of Hertfordshire, West Midlands Health Tech Innovation Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Septest
- ·The full record, as it builds
Funding rounds
No funding rounds for Septest are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Septest
Developer of point-of-care diagnostic tests designed to support early assessment of infection and immune response in clinical settings. The company offers a multi-biomarker blood test combining established immune markers, enabling clinicians in community, emergency, and acute care settings to differentiate infection risk and support earlier treatment decisions.
- Sector
- Healthcare
- HQ
- Hertfordshire, United Kingdom
- Founded
- 2022
- Employees
- 2
- Website
- septest.com/
- Ownership
- Privately Held (backing)
Septest doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Septest shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Septest in its N-PORT filings yet. We sweep new filings monthly.